Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

被引：5
|
作者：
Palmer, Daniel H.
Ma, Yuk Ting
Peck-Radosavljevic, Markus
Ross, Paul J.
Graham, Janet Shirley
Fartoux, Laetitia
Deptala, Andrzej
Wenz, Arne
Hocke, Julia
Loembe, Arsene-Bienvenu
Meyer, Tim
机构：
[1] Univ Liverpool, Canc Res UK Ctr, Liverpool L69 3BX, Merseyside, England
[2] Univ Birmingham, Sch Canc Sci, Birmingham, W Midlands, England
[3] Univ Hosp Birmingham NHS Fdn Trust, Ctr Canc, Birmingham, W Midlands, England
[4] Med Univ Wien, Dept Gastroenterol & Hepatol, Vienna, Austria
[5] Kings Coll Hosp NHS Fdn Trust, London, England
[6] Univ Glasgow, Beatson Labs, Glasgow, Lanark, Scotland
[7] Hop St Antoine, F-75571 Paris, France
[8] Minist Interior, Cent Clin Hosp, Dept Hematol & Oncol, Warsaw, Poland
[9] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[10] Boehringer Ingelheim BV, Alkmaar, Netherlands
[11] UCL Canc Inst, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.238
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
238
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.
    Cheng, Ann-Lii
    Yen, Chia-Jui
    Kim, Tae-You
    Feng, Yin-Hsun
    Chao, Yee
    Lin, Deng-Yn
    Loembe, Arsene-Bienvenu
    Hocke, Julia
    Choi, Caren
    Ryoo, Baek-Yeol
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [2] Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomised Phase II trial
    Yen, C.
    Kim, T. Y.
    Feng, Y. H.
    Chao, Y.
    Lin, D. Y.
    Studeny, M.
    Hocke, J.
    Huang, D. C. L.
    Ryoo, B. Y.
    Cheng, A. L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S612 - S612
  • [3] A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
    Yen, Chia-Jui
    Kim, Tae-You
    Feng, Yin-Hsun
    Chao, Yee
    Lin, Deng-Yn
    Ryoo, Baek-Yeol
    Huang, Dennis Chin-Lun
    Schnell, David
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Cheng, Ann-Lii
    [J]. LIVER CANCER, 2018, 7 (02) : 165 - 178
  • [4] Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    Llovet, J.
    Ricci, S.
    Mazzaferro, V.
    Hilgard, P.
    Raoul, J.
    Zeuzem, S.
    Poulin-Costello, M.
    Moscovici, M.
    Voliotis, D.
    Bruix, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials.
    Meyer, Tim
    Palmer, Daniel H.
    Chao, Yee
    Choi, Caren
    Deptala, Andrzej
    Fartoux, Laetitia
    Feng, Yin-Hsun
    Graham, Janet Shirley
    Hocke, Julia
    Kim, Tae-You
    Lin, Deng-Yn
    Ma, Yuk Ting
    Peck-Radosavljevic, Markus
    Ross, Paul J.
    Ryoo, Baek-Yeol
    Wenz, Arne
    Yen, Chia-Jui
    Loembe, Arsene-Bienvenu
    Cheng, Ann-Lii
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Combined analysis of two randomised Phase II trials comparing the efficacy and safety of nintedanib versus sorafenib in Caucasian and Asian patients with advanced hepatocellular carcinoma
    Palmer, D.
    Meyer, T.
    Chao, Y.
    Deptala, A.
    Fartoux, L.
    Feng, Y. -H.
    Graham, J.
    Lin, D. -Y.
    Ma, Y. T.
    Peck-Radosavljevic, M.
    Ross, P.
    Ryoo, B. -Y.
    Yen, C. -J.
    Hocke, J.
    Vlassak, S.
    Wenz, A.
    Loembe, A. -B.
    Cheng, A. -L.
    [J]. ANNALS OF ONCOLOGY, 2015, 26
  • [7] Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC)
    Palmer, Daniel H.
    Peck-Radosavljevic, Markus
    Ma, Yuk Ting
    Graham, Janet
    Fartoux, Laetitia
    Hubner, Richard
    Loembe, Arsene Bienvenu
    Studeny, Matus
    Hocke, Julia
    Meyer, Tim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomized phase II trials comparing nintedanib versus sorafenib
    Meyer, Tim
    Palmer, Daniel H.
    Cheng, Ann-Lii
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Yen, Chia-jui
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Cainap, Calin
    Qin, Shukui
    Huang, Wen-Tsung
    Chung, Ik-Joo
    Pan, Hongming
    Cheng, Ying
    Kudo, Masatoshi
    Kang, Yoon-Koo
    Chen, Pei-Jer
    Toh, Han Chong
    Gorbunova, Vera
    Eskens, Ferry
    Qian, Jiang
    McKee, Mark D.
    Ricker, Justin L.
    Carlson, Dawn M.
    El Nowiem, Saied
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [10] Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial
    Bruix, J.
    Merle, P.
    Granito, A.
    Huang, Y. -H.
    Bodoky, G.
    Yokosuka, O.
    Rosmorduc, O.
    Breder, V.
    Gerolami, R.
    Masi, G.
    Paul, J. Ross
    Qin, S.
    Song, T.
    Bronowicki, J. -P.
    Ollivier-Hourmand, I.
    Kudo, M.
    LeBerre, M. -A.
    Baumhauer, A.
    Meinhardt, G.
    Han, G.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : 140 - +
12345